Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The world’s population is aging and rapidly increasing; it is estimated to reach 9.4 billion in 2050, with 1.5 billion people older than 65 years.1 In parallel to an aging population, cancer incidence is expected to rise, and in 2035 it is estimated that 70% of diagnosed cancers in the United States will occur in patients older than 65 years.2 It is logical to assume that this trend will also occur in the primary brain tumor, glioblastoma (GBM). This presents a problem for neuro-oncologists because older patients have been historically underrepresented in neuro-oncology trials. The lack of representation coupled with toxicity concerns often leads to undertreatment in these patients. Given the imminent increasing numbers of elderly patients with GBM, more representation in clinical studies, as well as clear treatment guidelines, is needed for this population.
Clark SW. The Age Factor in the Treatment of Glioblastoma. JAMA Neurol. 2016;73(7):783-784. doi:10.1001/jamaneurol.2016.1331